Table 1. Baseline characteristics of 384 patients at the time of NSCLC diagnosis.
| Characteristics | Total (%) | Brain metastasis | P | |
|---|---|---|---|---|
| BM+ (n = 150) | BM- (n = 234) | |||
| Gender | 0.001 | |||
| Male | 202 (52.6) | 63 (31.2) | 139 (68.8) | |
| Female | 182 (47.4) | 87 (47.8) | 95 (52.2) | |
| Age (years) | <0.001 | |||
| ≧60 | 273 (71.1) | 89 (32.6) | 184 (67.4) | |
| <60 | 111 (28.9) | 61 (55.0) | 50 (45.0) | |
| Smoking | <0.001 | |||
| Current/former | 166 (43.2) | 48 (28.9) | 118 (71.1) | |
| Never | 218 (56.8) | 102 (46.8) | 116 (53.2) | |
| Histology | 0.005 | |||
| Adenocarcinoma | 320 (83.3) | 135 (42.2) | 185 (57.8) | |
| Non-adenocarcinoma | 64 (16.7) | 15 (23.4) | 49 (76.6) | |
| Stage | <0.001 | |||
| IIIB - IV | 323 (84.1) | 139 (43.0) | 184 (57.0) | |
| I - IIIA | 61 (15.9) | 11 (18.0) | 50 (82.0) | |
| EGFR | <0.001 | |||
| WT | 198 (51.6) | 54 (27.3) | 144 (72.7) | |
| Mut | 186 (48.4) | 96 (51.6) | 90 (48.4) | |
| EGFR Mut subtype (n = 186) | 0.766 | |||
| Exon 19 | 79 (42.5) | 42 (53.1) | 37 (46.9) | |
| L858R | 97 (52.2) | 48 (49.5) | 49 (50.5) | |
| Uncommon | 10 (5.4) | 6 (60.0) | 4 (40.0) | |
NSCLC: non-small cell lung cancer; BM: brain metastases; EGFR: epidermal growth factor receptor; Mut: mutated; WT: wild type. The categorical data were presented as numbers (percentages) and the comparisons between groups used the chi-squared test. Non-adenocarcinoma group included squamous cell carcinoma, large cell carcinoma and NSCLC-not otherwise specified in this analysis. Uncommon mutations included 3 with an exon 18 mutation, 6 with an exon 20 insertion, and 1 with an exon 18 mutation and exon 20 insertion.